Compare SFHG & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFHG | ABP |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | Hong Kong | United States |
| Employees | 216 | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 12.5M |
| IPO Year | 2024 | N/A |
| Metric | SFHG | ABP |
|---|---|---|
| Price | $0.78 | $4.45 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 135.9K | 14.3K |
| Earning Date | 10-30-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,577,200.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.56 | ★ 50.00 |
| 52 Week Low | $0.32 | $3.78 |
| 52 Week High | $2.32 | $49.50 |
| Indicator | SFHG | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 53.79 | 44.24 |
| Support Level | $0.70 | $3.98 |
| Resistance Level | $0.84 | $4.30 |
| Average True Range (ATR) | 0.09 | 0.35 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 28.31 | 51.34 |
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.